Home > Insider Trading > Filing (0000899243-20-008495)

Filing Details

Accession Number:: 0000899243-20-008495
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-16 17:17:07
Reporting Period:: 2020-03-12

Accepted Time:: 2020-03-16 17:17:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Imara Inc.	IMRA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1572451	P David Bonita	C/O Imara Inc., 116 Huntington Ave, 6Th Floor Boston MA 02116		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-12	937,500	$16.00	937,500	No	4	P	Indirect	By OrbiMed Private Investments VII, LP
Common Stock	Acquisiton	2020-03-16	1,594,902	$0.00	2,532,402	No	4	C	Indirect	By OrbiMed Private Investments VII, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By OrbiMed Private Investments VII, LP
No	4	C	Indirect	By OrbiMed Private Investments VII, LP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-03-16	10,046,294	$0.00	1,594,902	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2020-03-16	15,457	$0.00	15,457	$16.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
15,457		2030-03-15	No	4	A	Direct

Footnotes

On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The securities are held by OrbiMed Private Investments VII, LP, or OPI VII. OrbiMed Capital GP VII LLC, or GP VII, is general partner of OPI VII, and OrbiMed Advisors LLC, or Advisors, is the managing member of GP VII. The Reporting Person is a member of Advisors. By virtue of such relationships, GP VII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. Both GP VII and Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OPI VII. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPI VII.
The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
The option vests in three equal installments on March 16, 2021, 2022 and 2023.
Pursuant to an agreement with Advisors and GP VII, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII.